Financial Report: Merck

Merck

2Q Revenues: $9.8 billion (+1%)

2Q Earnings: $1.2 billion (+100%)

YTD Revenues: $19.2 billion (flat)

YTD Earnings: $2.3 billion (+42%)

Comments: Pharmaceutical sales were up 2% to $8.7 billion, with higher sales in oncology, hospital acute care, the cardiovascular franchise and vaccines. KEYTRUDA sales were $314 million in the quarter, up from $110 million 2Q15. CUBICIN sales were $357 million, up 22%. The company launched HCV drug ZEPATIER, which had sales of $112 million in the quarter. REMICADE sales were down 26% to $339 million, due to the impact of biosimilar competition. JANUVIA sales were $1.6 billion, up 2%. ZETIA/VYTORIN sales were $994 million, up 4%. GARDASIL sales were down 7% to $393 million.